Matthew Charles Tindall

IQVIA RDS Consulting, Inc. provides global regulatory, compliance, and validation consulting services. The company offers strategic regulatory consulting in the areas of quality systems development and optimization, FDA enforcement solutions, validation, and bioresearch monitoring. It provides services to the pharmaceutical, biotechnology, and medical device industries. The company was founded in 2001 and is located in Vernon Hills, IL.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

RRD International LLC develops biopharmaceutical products. The firm offers product development support to biotechnology, pharmaceutical and medical device companies. Its services include development, strategic planning, program management and research. The company was founded by Frank L. Hurley and Charles W. Finn in 2002 and is headquartered in Rockville, MD.

Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA.

Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA.

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

Myotherix, Inc. operates as a biopharmaceutical company focuses on the development of therapies. It focuses on the development of innovative therapies for patients suffering from Duchenne muscular dystrophy and other muscle disorders for which there are no treatments. The company was founded by John Kincaid and is headquartered in Emeryville, CA.

Willow Neuroscience, Inc. operates as a biotechnology company that wholesales pharmaceutical products. The company is headquartered in Emeryville, CA.